GenEdit Announces Series A Financing and Provides Research Update at TIDES 2021

  • Funding will advance development of NanoGalaxyTM, the company’s proprietary platform of polymer nanoparticles optimized for tissue-selective delivery of genetic medicines, and selection of therapeutic candidates for clinical development by GenEdit
  • Data presented today show GenEdit’s polymer nanoparticles can be optimized for tissue-selective delivery of a range of genetic medicine modalities and dosed multiple times without diminished function of the genetic payload in animal models

SOUTH SAN FRANCISCO, Calif., September 23, 2021 – GenEdit, Inc., a biotechnology company with a mission to develop curative therapies through targeted in vivo delivery of genetic medicines, today announced that it has closed a $26 million Series A financing. New investors Eli Lilly, KTB Network, Ltd., Company K Partners, Korea Investment Partners, DAYLI Partners, KB Investment, IMM Investment, and TIMEFOLIO Asset Management, join existing investors DCVC Bio, SK Holdings, Bow Capital, and Sequoia Capital, participating in the financing. The funding will support the further development of GenEdit’s NanoGalaxyTM platform of non-viral, non-lipid polymer nanoparticles, and the selection for clinical development of therapeutic candidates targeting diseases of the nervous system.

In addition, GenEdit today disclosed new in vivo data demonstrating tissue-selective delivery after intravenous or intrathecal administration of its polymer nanoparticles. This selectivity was achieved through optimization of polymer structure utilizing the NanoGalaxy platform. Additional data show GenEdit’s polymer nanoparticles can be dosed multiple times with functional activity of the payload maintained in each subsequent dose. GenEdit’s CEO and Cofounder Kunwoo Lee, Ph.D. will present this data at 2:30 pm ET today at TIDES 2021 in Room 204AB in a talk entitled, “Delivery of Genetic Medicines with Non-Viral Polymer Nanoparticles.”

“With this financing, we are exploring the universe of opportunities within GenEdit’s NanoGalaxy platform to treat serious diseases without effective treatment options,” said Dr. Lee. “The data presented today indicates we can overcome the historic challenges in the field of gene therapy and establishes the feasibility of using GenEdit’s polymer nanoparticles to deliver genetic medicines to a variety of tissues, including the CNS, with the potential for delivering a therapeutic effect.”

GenEdit’s NanoGalaxy platform includes thousands of chemically distinct polymers, each with unique properties making them amenable to targeting different tissues and cell types and carrying diverse genetic medicine payloads. GenEdit’s polymer nanoparticles can deliver DNA, RNA, or CRISPR ribonucleoprotein, depending on the requirement to add, delete, edit, or silence a gene for therapeutic effect.

“With its NanoGalaxy platform, the GenEdit team has achieved impressive delivery to cells of the central nervous system and has a tunable platform to target genetic medicines to different tissue types,” said Andrew Adams, Vice President of New Therapeutic Modalities at Eli Lilly and GenEdit Board observer. “Solving the delivery problem is what will truly launch genetic medicines to being an essential therapeutic modality for a wide range of diseases.”


About GenEdit, Inc.

At GenEdit, our mission is to develop curative therapies through targeted in vivo delivery of genetic medicines. Our NanoGalaxy™ platform of non-viral, non-lipid polymer nanoparticles will enable a universe of opportunities to launch the next generation of safe and effective genetic medicines. To bring these medicines to patients, we are developing our own internal pipeline and delivering a wide variety of therapeutic payloads for our partners’ programs. For more info, visit



Company Contact: Kunwoo Lee, Ph.D., GenEdit, Inc.,, +1 (510) 766-2575

Media Contact: Jessica Yingling, Ph.D., Little Dog Communications Inc.,, +1 (858) 344-8091